Resource Guide: Ibrance Interstitial Lung Disease compensation overview for North Carolina

Below is a working bibliography of trusted health, pharmacovigilance, and legal-analysis sources, compiled for open research.

Primary topic reference

Ibrance Interstitial Lung Disease compensation overview for North Carolina

Detailed background, context, and analysis on this topic, compiled for open research purposes.

Centers for Disease Control and Prevention (CDC)

Reference: Centers for Disease Control and Prevention (CDC)

Authoritative source for clinical, regulatory, and public-health background reading.

U.S. Food and Drug Administration (FDA)

Reference: U.S. Food and Drug Administration (FDA)

Authoritative source for clinical, regulatory, and public-health background reading.

European Medicines Agency (EMA)

Reference: European Medicines Agency (EMA)

Authoritative source for clinical, regulatory, and public-health background reading.